Read review Dihexa for Migraine & Chronic Migraine The May 2024 NICE TA973 atogepant (Aquipta, AbbVie) approval, the rimegepant / erenumab / galcanezumab / fremanezumab / eptinezumab CGRP pathway, 2025 chronic-migraine hippocampal atrophy & accelerated brain ageing research, the Tanure BDNF-elevated-in-attack paradox, NICE NG150, and the ~10 million UK migraine population
Healing Peptide Flexibility BPC-157, TB-500, and GHK-Cu show flexible timing requirements
NAD+/MOTS-C/5-Amino-1MQ, also called Mitoprime, is a three-peptide blend containing NAD+ (100mg), MOTS-C (10mg), and 5-Amino-1MQ (10mg) in a single 120mg lyophilized vial
Efficacy of sublingual and oral vitamin B12 versus intramuscular injection